Navigation Links
Poniard Pharmaceuticals Announces Upcoming Conference Participation
Date:7/29/2008

SOUTH SAN FRANCISCO, Calif., July 29 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that Ronald A. Martell, president and chief operating officer, will participate in two upcoming conferences in August during which he will provide a corporate overview, including a discussion of the clinical development program and regulatory strategy for picoplatin, the Company's lead product candidate.

* Oppenheimer & Co. Inc.'s Small & Mid Cap Clinical & Regulatory Conference on Monday, August 4, at 8:40 a.m. Eastern Time at the Oppenheimer office in New York. Mr. Martell will discuss Poniard's clinical development programs and regulatory strategy, and then participate in a subsequent panel discussion, entitled "Designing A Pivotal Program with an Eye Towards Approval." During this discussion, which begins at 9:55 a.m., Mr. Martell will discuss the regulatory path to approval for picoplatin.

* BMO Capital Markets' 2008 Focus on Healthcare Conference on Tuesday, August 5, at 9:00 a.m. Eastern Time at the Millennium Broadway Hotel in New York.

A live audio webcast of each Poniard presentation will be available for 10 business days on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancers, as well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by any regulatory authority for use in humans. For additional information please visit http://www.poniard.com.

(C) 2008 Poniard Pharmaceuticals, Inc. All Rights Reserved. Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
2. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
3. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
4. Poniard Pharmaceuticals Announces Upcoming Conference Participation
5. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
6. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
7. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
10. VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC
11. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... 2017 , ... Customers often prefer PLC and network ... METTLER TOLEDO has released two new videos that show how they have solved ... ACT350 into Siemens and Allen Bradley PLCs is easy and fast. ...
(Date:5/22/2017)... ... May 22, 2017 , ... ... it is exhibiting in booth B2 at the Association for Pathology Informatics ... , In addition to demonstrating its Cancer Diagnostic Cockpit and Consultation Portal, ...
(Date:5/19/2017)... ... May 19, 2017 , ... In response to the strong ... Biodex Medical Systems, Inc. announces the release of their Gait Trainer 3 with an ... with a biomedical system to aid in rehabilitating individuals with cerebral palsy, traumatic brain ...
(Date:5/18/2017)... ... 18, 2017 , ... Lajollacooks4u has added another option for ... team-building package designed for groups of 10-30 people. Guests can choose their ... such as Blackened Shrimp with Edamame Salad, Pizza Rolls with Pepperoni and Mushrooms ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities and ... and behavioral), by technology (fingerprint, AFIS, iris recognition, facial ... and others), by end use industry (government and law ... financial and banking, and others), and by region ( ... , Asia Pacific , and the ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
(Date:3/23/2017)... India , March 23, 2017 The report "Gesture ... Touchless Biometric), Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, ... at a CAGR of 29.63% between 2017 and 2022. ... ... ...
Breaking Biology News(10 mins):